CeriBell (NASDAQ:CBLL) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS

CeriBell (NASDAQ:CBLL) released its earnings results on Tuesday. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07, FiscalAI reports. CeriBell had a negative net margin of 59.97% and a negative return on equity of 30.99%. The company had revenue of $24.78 million for the quarter, compared to analyst estimates of $23.95 million.

Here are the key takeaways from CeriBell’s conference call:

• Strong top-line growth and solid cash runway — Q4 revenue was $24.8M (+34% YoY) and full-year 2025 revenue was $89.1M (+36%); management guides 2026 revenue of $111M–$115M and ended 2025 with $159M in cash and marketable securities.
• Regulatory and access wins materially expand addressable market — FedRAMP High approval (opens VA system), FDA 510(k) clears for neonatal/pediatric seizure detection, FDA clearance for delirium algorithm, and Breakthrough Device designation for inpatient LVO stroke; management now estimates TAM ≈ $3.5B.
• Commercial traction with room to scale — 647 active hospital accounts (118 net adds in 2025), expansion from ~35 to ~55 territories, and a playbook to drive deeper utilization (currently ~30% penetration) plus a new system-level sales focus expected to accelerate account adds in 2H 2026–2027.
• Rising operating expenses, litigation and margin pressure — FY operating expenses rose 42% to $136.7M and net loss was $53.4M; management expects elevated OpEx (R&D, IP litigation) and mid-80% gross margins in 2026 due to tariff-related cost shifts.
• New product timing limits near-term revenue impact — Neonatal/pediatric full commercial launch targeted for Q2 2026 with modest 2026 contribution (material revenue expected in 2027+); delirium pilots and NTAP pursuit could drive upside but are expected to scale later in 2026–2027.

CeriBell Trading Down 3.9%

NASDAQ:CBLL opened at $19.12 on Thursday. The stock’s 50 day moving average price is $21.20 and its 200 day moving average price is $16.19. The company has a market capitalization of $709.28 million, a PE ratio of -13.09 and a beta of 1.03. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. CeriBell has a 52-week low of $10.01 and a 52-week high of $25.98.

Insiders Place Their Bets

In related news, Director William W. Burke sold 32,728 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $22.02, for a total transaction of $720,670.56. Following the completion of the sale, the director owned 17,391 shares in the company, valued at $382,949.82. This represents a 65.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Xingjuan Chao sold 79,000 shares of CeriBell stock in a transaction on Monday, January 5th. The shares were sold at an average price of $21.27, for a total transaction of $1,680,330.00. Following the completion of the transaction, the chief executive officer owned 741,248 shares in the company, valued at approximately $15,766,344.96. This represents a 9.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 342,085 shares of company stock worth $6,977,156. Corporate insiders own 20.10% of the company’s stock.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in CeriBell by 6,424.8% in the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after acquiring an additional 374,179 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of CeriBell by 109.9% in the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after purchasing an additional 17,177 shares during the period. New York State Common Retirement Fund boosted its holdings in CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after buying an additional 5,200 shares in the last quarter. Quantbot Technologies LP grew its position in CeriBell by 70.3% during the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after buying an additional 6,401 shares during the period. Finally, Invesco Ltd. purchased a new position in CeriBell in the second quarter valued at about $197,000.

Key Stories Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 results beat expectations: CeriBell reported a loss of $0.36/sh vs. consensus -$0.43 and revenue of $24.78M vs. est. $23.95M — an earnings and top-line beat that supports the bullish case. Press Release
• Positive Sentiment: Earnings call commentary highlighted revenue surge and market expansion, reinforcing investor confidence in growth trajectory and addressable market opportunities. Earnings Call Transcript
• Neutral Sentiment: FY2026 revenue guidance set at $111M–$115M vs. consensus $112.7M — roughly in line with street expectations but EPS guidance was not provided, leaving some uncertainty about profitability trajectory. Company Results / Guidance
• Neutral Sentiment: Short-interest notice in the feed appears inconsistent/ambiguous (reports 0 shares and NaN changes), so it offers no clear signal on bearish positioning. Short Interest / Stock Page
• Negative Sentiment: Multiple insider sales reported over Feb. 23–24: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph Manni and VP David Foehr sold small portions of their holdings at ~$19.79–19.98/share. While sizes are small relative to total holdings, clustered executive selling can weigh on sentiment short-term. (See SEC filings for details.) Insider Filing Example

Wall Street Analyst Weigh In

CBLL has been the topic of a number of analyst reports. JPMorgan Chase & Co. reduced their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Canaccord Genuity Group raised their target price on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. BTIG Research reissued a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research report on Wednesday, January 28th. Finally, TD Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $24.67.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.